LMO4 and PPARG

Number of citations of the paper that reports this interaction (PubMedID 19020036)
24

Data Source:
BioGRID (affinity chromatography technology, two hybrid, pull down)

		LMO4	PPARG
Description		LIM domain only 4	peroxisome proliferator activated receptor gamma
Image
GO Annotations	Cellular Component	Transcription Regulator Complex Cell Leading Edge RNA Polymerase II Transcription Regulator Complex	Chromatin Nucleus Nucleoplasm Cytosol Intracellular Membrane-bounded Organelle Receptor Complex RNA Polymerase II Transcription Regulator Complex
	Molecular Function	Protein Binding Transcription Factor Binding Metal Ion Binding	Transcription Cis-regulatory Region Binding RNA Polymerase II Cis-regulatory Region Sequence-specific DNA Binding DNA-binding Transcription Factor Activity, RNA Polymerase II-specific DNA-binding Transcription Repressor Activity, RNA Polymerase II-specific DNA Binding Chromatin Binding Double-stranded DNA Binding DNA-binding Transcription Factor Activity Nuclear Receptor Activity Prostaglandin Receptor Activity Protein Binding Protein C-terminus Binding Transcription Factor Binding Zinc Ion Binding Enzyme Binding Peptide Binding Identical Protein Binding Sequence-specific DNA Binding Protein Self-association Retinoid X Receptor Binding Arachidonic Acid Binding DNA Binding Domain Binding LBD Domain Binding Alpha-actinin Binding R-SMAD Binding E-box Binding STAT Family Protein Binding DNA-binding Transcription Factor Binding
	Biological Process	Neural Tube Closure Ventricular Septum Development Ventral Spinal Cord Interneuron Differentiation Spinal Cord Motor Neuron Differentiation Spinal Cord Association Neuron Differentiation Regulation Of Cell Migration Negative Regulation Of Protein-containing Complex Assembly Positive Regulation Of Kinase Activity Regulation Of Cell Fate Specification Positive Regulation Of Transcription By RNA Polymerase II Thymus Development Regulation Of Cell Activation	Negative Regulation Of Transcription By RNA Polymerase II Placenta Development Regulation Of Transcription By RNA Polymerase II Lipid Metabolic Process Fatty Acid Metabolic Process Activation Of Cysteine-type Endopeptidase Activity Involved In Apoptotic Process Signal Transduction G Protein-coupled Receptor Signaling Pathway Response To Nutrient Regulation Of Blood Pressure Hormone-mediated Signaling Pathway Positive Regulation Of Gene Expression Negative Regulation Of Gene Expression Macrophage Derived Foam Cell Differentiation Negative Regulation Of Macrophage Derived Foam Cell Differentiation Positive Regulation Of Pathway-restricted SMAD Protein Phosphorylation Positive Regulation Of Cholesterol Efflux Negative Regulation Of Cholesterol Storage Negative Regulation Of Sequestering Of Triglyceride Long-chain Fatty Acid Transport Negative Regulation Of Angiogenesis Regulation Of Lipid Metabolic Process Cell Differentiation Monocyte Differentiation BMP Signaling Pathway Negative Regulation Of Transforming Growth Factor Beta Receptor Signaling Pathway Negative Regulation Of BMP Signaling Pathway Epithelial Cell Differentiation Cellular Response To Insulin Stimulus Response To Lipid Peroxisome Proliferator Activated Receptor Signaling Pathway Glucose Homeostasis Regulation Of Circadian Rhythm Lipoprotein Transport Positive Regulation Of DNA Binding Negative Regulation Of MAP Kinase Activity Negative Regulation Of Blood Vessel Endothelial Cell Migration Innate Immune Response Cell Fate Commitment Positive Regulation Of Fat Cell Differentiation Negative Regulation Of Osteoblast Differentiation Negative Regulation Of Transcription, DNA-templated Positive Regulation Of Transcription, DNA-templated Positive Regulation Of Fatty Acid Metabolic Process Positive Regulation Of Transcription By RNA Polymerase II Retinoic Acid Receptor Signaling Pathway Cell Maturation Rhythmic Process Negative Regulation Of Smooth Muscle Cell Proliferation Negative Regulation Of Inflammatory Response White Fat Cell Differentiation Positive Regulation Of DNA-binding Transcription Factor Activity Lipid Homeostasis Negative Regulation Of Interferon-gamma-mediated Signaling Pathway Positive Regulation Of SMAD Protein Signal Transduction Negative Regulation Of SMAD Protein Signal Transduction Negative Regulation Of Pathway-restricted SMAD Protein Phosphorylation Regulation Of Cholesterol Transporter Activity Negative Regulation Of Gene Silencing By MiRNA Cellular Response To Low-density Lipoprotein Particle Stimulus Negative Regulation Of Mitochondrial Fission Negative Regulation Of Pri-miRNA Transcription By RNA Polymerase II Positive Regulation Of Pri-miRNA Transcription By RNA Polymerase II Negative Regulation Of Cellular Response To Transforming Growth Factor Beta Stimulus Negative Regulation Of Vascular Associated Smooth Muscle Cell Proliferation Negative Regulation Of Receptor Signaling Pathway Via STAT Positive Regulation Of Vascular Associated Smooth Muscle Cell Apoptotic Process Negative Regulation Of Vascular Endothelial Cell Proliferation Positive Regulation Of Low-density Lipoprotein Receptor Activity Negative Regulation Of Signaling Receptor Activity
Pathways			PPARA activates gene expression Transcriptional regulation of white adipocyte differentiation Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Regulation of PTEN gene transcription Regulation of PTEN gene transcription MECP2 regulates transcription factors
Drugs			alpha-Linolenic acid Icosapent Troglitazone Mesalazine Valproic acid Indomethacin Rosiglitazone Fenoprofen Nateglinide Sulfasalazine Clofazimine Repaglinide Telmisartan Balsalazide Ibuprofen Glipizide Amiodarone Pioglitazone Mitiglinide Bezafibrate Flufenamic acid Resveratrol Phthalic Acid Capric acid Doconexent Oleic Acid (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID Reglitazar Elafibranor AMG-131 CLX-0921 Muraglitazar Ertiprotafib Ragaglitazar Tesaglitazar (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid 9(S)-HODE difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID 3-(5-methoxy-1H-indol-3-yl)propanoic acid Indeglitazar (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid 2-chloro-5-nitro-N-phenylbenzamide (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE Triclosan (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid Aleglitazar Clinofibrate Cannabidiol Lobeglitazone Ciglitazone Dexibuprofen Omega-3 fatty acids Curcumin Arhalofenate Isoflavone Naveglitazar Fenofibric acid Fish oil Medical Cannabis Nabiximols Darglitazone Curcumin sulfate
Diseases
GWAS		Academic attainment (English) ( 33594131) Age at first sexual intercourse ( 34211149) Alanine aminotransferase levels ( 33547301) Angiotensin-converting enzyme inhibitor intolerance ( 28030426) Aspartate aminotransferase levels ( 33547301) Breast cancer ( 27354352) Eosinophil counts ( 29403010) Gait rhythm ( 26219847) Glaucoma (primary open-angle) ( 29891935) Photic sneeze reflex ( 27182965) Prostate-specific antigen levels ( 28139693) Response to TNF antagonist treatment ( 18615156) Resting heart rate ( 27798624) White blood cell count (basophil) ( 29403010) White blood cell types ( 21738478)	Adult body size ( 32376654) Alanine aminotransferase levels ( 33547301 34315874) Apolipoprotein A1 levels ( 32203549) Apolipoprotein B levels ( 32203549) Arterial stiffness index ( 31235810) Aspartate aminotransferase levels ( 33547301 34315874) Body fat percentage and fasting insulin (pairwise) ( 33619380) Body fat percentage and type 2 diabetes (pairwise) ( 33619380) Body mass index ( 28892062 25673413 29273807) Body mass index and fasting insulin (pairwise) ( 33619380) Body mass index and type 2 diabetes (pairwise) ( 33619380) Body shape index ( 34021172) Cholesterol, total ( 25961943) Drug-induced liver injury ( 22968431) Endometrial cancer ( 30093612) Endometrial cancer (endometrioid histology) ( 30093612) Eosinophil counts ( 32888494 27863252) Eosinophil percentage of granulocytes ( 27863252) Eosinophil percentage of white cells ( 32888494 27863252) Fasting blood insulin ( 25631608) Fasting blood insulin (BMI interaction) ( 22581228) Fasting blood insulin adjusted for BMI ( 25625282) Fasting insulin ( 34059833) Gut microbiota (functional units) ( 27694959) HDL cholesterol ( 30275531) HDL cholesterol levels ( 32203549) HDL cholesterol levels in HIV infection ( 33109212) Heel bone mineral density ( 30598549) Hematocrit ( 32888494 27863252) Hemoglobin ( 32888494) Hemoglobin concentration ( 27863252) Hemoglobin levels ( 32327693) High density lipoprotein cholesterol levels ( 29403010 33339817) High light scatter reticulocyte count ( 32888494) Hip circumference adjusted for BMI ( 34021172 25673412) Hip index ( 34021172) Idiopathic osteonecrosis of the femoral head ( 31135556) LDL cholesterol ( 25961943) LDL cholesterol levels ( 32203549 30698716) LDL cholesterol levels in current drinkers ( 30698716) LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) Liver enzyme levels (alanine transaminase) ( 33972514) Liver enzyme levels (alkaline phosphatase) ( 33972514) Liver enzyme levels (gamma-glutamyl transferase) ( 33972514) Medication use (drugs used in diabetes) ( 31015401) Medication use (HMG CoA reductase inhibitors) ( 31015401) Medication use (thyroid preparations) ( 31015401) Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI) ( 27416945) Neutrophil percentage of granulocytes ( 27863252) Plasminogen activator inhibitor type 1 levels (PAI-1) ( 22990020) Platelet count ( 29403010) Platelet distribution width ( 32888494) Plateletcrit ( 32888494) Potassium levels ( 29403010) Red blood cell count ( 32888494) Red cell distribution width ( 32888494) Serum alkaline phosphatase levels ( 33547301) Sexual dimorphism in anthropometric traits ( 23754948) Spleen volume ( 34128465) Systemic lupus erythematosus ( 28714469) Thyroid stimulating hormone levels ( 32769997) Triglyceride levels ( 32203549 32154731) Type 2 diabetes ( 22885922 18372903 24509480 30054458 29358691 30297969 29632382 31118516 32499647 20581827 17463246 30718926 17463248 17463249 28869590) Type 2 diabetes (adjusted for BMI) ( 29632382) Type 2 diabetes or prostate cancer (pleiotropy) ( 33290408) Waist circumference ( 31453325) Waist circumference adjusted for body mass index ( 34021172) Waist circumference variance ( 31453325) Waist-hip index ( 34021172) Waist-hip ratio ( 25673412) Waist-hip ratio and type 2 diabetes (pairwise) ( 33619380) Waist-to-hip ratio adjusted for BMI ( 34021172 26426971) Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour) ( 28443625) Waist-to-hip ratio adjusted for BMI (age <50) ( 26426971) Waist-to-hip ratio adjusted for BMI (age >50) ( 26426971) Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction) ( 28448500) Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction) ( 28443625) Waist-to-hip ratio adjusted for BMI in active individuals ( 28448500) Waist-to-hip ratio adjusted for BMI in non-smokers ( 28443625) Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test) ( 26426971) Waist-to-hip ratio adjusted for body mass index ( 25673412 28448500) Walking pace ( 33128006) Youthful appearance (self-reported) ( 32339537)
Interacting Genes		131 interacting genes: AARD ABI2 ADAMTSL4 AMOT AMOTL2 ARNT2 BANP BBS2 BCAS2 BIRC7 BRCA1 C12orf40 CALCOCO2 CCDC102B CCDC120 CEP170P1 COG6 CRNN CRYBB2 CSNK2B CTBP2 CYSRT1 DDB1 DEAF1 DES DYNC1H1 ECM1 ERCC6L EXOSC8 FAM228A FHL3 GABPB1 GADD45A GOLGA2 GOLGA6L9 GRHL2 GSK3B HELT HGS HSF2BP ID3 IKZF1 IKZF3 ITSN1 KANK2 KATNBL1 KIAA1958 KIF3B KPNA1 KRT15 KRT31 KRT33B KRT34 KRT38 KRT39 KRT40 KRT74 KRT75 KRT76 KRTAP11-1 KRTAP3-1 KYNU L3MBTL3 LASP1 LDB1 LDB2 LMO2 LZTS1 MCCD1 MERTK METTL27 MID2 MTA1 MTUS2 MYOD1 MYOZ3 N4BP3 NFKBID NFYC NHLH1 NME4 NONO NRF1 PDE4DIP PELO PER2 PITPNB PLK1 PPARG PPP1R32 QRICH1 RBAK RBBP8 RBPMS RCN1 RNF8 ROPN1 RPS6KA6 RSPH6A SEC24D SLC15A2 SMAD4 SMAD9 STAT5B SUOX TCF21 TCF4 TEX14 TFIP11 TINAGL1 TLE5 TNFSF11 TP53BP2 TRAF5 TRIM27 TRIM54 TSEN15 TTLL7 UBQLN2 VMAC VPS52 WASHC1 ZBTB43 ZMYND12 ZNF135 ZNF202 ZNF213 ZNF397 ZNF410 ZNF467 ZNF675	114 interacting genes: ADCY4 ALOX15B ANP32A APP BCAS2 BRD8 CDC34 CDK5 CEP350 CNOT1 COPS5 CREBBP DNTTIP2 EDF1 EGFR EP300 ESRRA FABP1 FHOD1 FOXO1 GADD45B GADD45G GATA5 GRIP1 HDAC1 HDAC3 HDAC4 HELZ2 HMGA1 IGFBP3 IKBKB JAZF1 JMJD1C JUN JUND KAT2A KAT5 KCTD13 KIF11 KIF1A KLF5 LMO4 LRIF1 MAFF MAP2K1 MAPK1 MAPK8 MAPK9 MED1 MED24 MFHAS1 MIF4GD MSX2 MUC1 NCOA1 NCOA2 NCOA3 NCOA4 NCOA6 NCOR1 NCOR2 NFE2L2 NFE2L3 NFKB1 NFKBIB NR0B1 NR0B2 NR1H2 NR1H3 NR2E3 NR4A1 NR4A2 NRIP1 NSD1 PAK4 PDIA2 PHB2 PML POU1F1 PPARGC1A PPM1B PRKCA RAD54L2 RANBP9 RARA RB1 ROBO4 RXRA RXRB RXRG SERPINH1 SFPQ SIRT1 SMARCD3 SRSF1 STAT6 STUB1 SVIL SYT1 TFAP2A TNP1 TRIM24 TRIP4 UBC UBE2I USP7 VDR ZBTB20 ZBTB3 ZBTB5 ZBTB9 ZNF496 ZNHIT3 ZSCAN1
Entrez ID		8543	5468
HPRD ID		09122	03288
Ensembl ID		ENSG00000143013	ENSG00000132170
Uniprot IDs		P61968	A0A494C1F9 D2KUA6 E9PFV2 E9PFX5 P37231
PDB IDs		2L4Z	1FM6 1FM9 1I7I 1K74 1KNU 1NYX 1PRG 1RDT 1WM0 1ZEO 1ZGY 2ATH 2F4B 2FVJ 2G0G 2G0H 2GTK 2HFP 2HWQ 2HWR 2I4J 2I4P 2I4Z 2OM9 2P4Y 2POB 2PRG 2Q59 2Q5P 2Q5S 2Q61 2Q6R 2Q6S 2Q8S 2QMV 2VSR 2VST 2VV0 2VV1 2VV2 2VV3 2VV4 2XKW 2YFE 2ZK0 2ZK1 2ZK2 2ZK3 2ZK4 2ZK5 2ZK6 2ZNO 2ZVT 3ADS 3ADT 3ADU 3ADV 3ADW 3ADX 3AN3 3AN4 3B0Q 3B0R 3B1M 3B3K 3BC5 3CDP 3CDS 3CS8 3CWD 3D6D 3DZU 3DZY 3E00 3ET0 3ET3 3FEJ 3FUR 3G9E 3GBK 3H0A 3HO0 3HOD 3IA6 3K8S 3KMG 3LMP 3NOA 3OSI 3OSW 3PBA 3PO9 3PRG 3QT0 3R5N 3R8A 3R8I 3S9S 3SZ1 3T03 3TY0 3U9Q 3V9T 3V9V 3V9Y 3VJH 3VJI 3VN2 3VSO 3VSP 3WJ4 3WJ5 3WMH 3X1H 3X1I 4A4V 4A4W 4CI5 4E4K 4E4Q 4EM9 4EMA 4F9M 4FGY 4HEE 4JAZ 4JL4 4L96 4L98 4O8F 4OJ4 4PRG 4PVU 4PWL 4R06 4R2U 4R6S 4XLD 4XTA 4XUH 4XUM 4Y29 4YT1 5AZV 5DSH 5DV3 5DV6 5DV8 5DVC 5DWL 5F9B 5GTN 5GTO 5GTP 5HZC 5JI0 5LSG 5TTO 5TWO 5U5L 5UGM 5WQX 5WR0 5WR1 5Y2O 5Y2T 5YCN 5YCP 5Z5S 5Z6S 6AD9 6AN1 6AUG 6AVI 6C1I 6C5Q 6C5T 6D3E 6D8X 6D94 6DBH 6DCU 6DGL 6DGO 6DGP 6DGQ 6DGR 6DH9 6DHA 6E5A 6ENQ 6F2L 6FZF 6FZG 6FZJ 6FZP 6FZY 6ICJ 6IJR 6IJS 6ILQ 6IZM 6IZN 6JEY 6JF0 6JQ7 6K0T 6KTM 6KTN 6L89 6L8B 6MCZ 6MD0 6MD1 6MD2 6MD4 6MS7 6O67 6O68 6ONI 6ONJ 6PDZ 6QJ5 6T6B 6T9C 6TDC 6TSG 6VZL 6VZM 6VZN 6VZO 6Y3U 6ZLY 7AHJ 7AWC 7AWD 7JQG 7LOT
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?